Maegim한국어

제일약품

271980KOSPISector: Pharma & Biotech
₩9,690▼ 4.25%Market cap ₩142.5BAs of Jul 21, 2026 close · updated once daily
B
Grade B65.3 ptsTop 21% of 2,523 stocks
Financial strength
53.7
Growth momentum
54.2
Price attractiveness
86.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

53.7
How much debt does it carry relative to equity?
Debt-to-equity ratio
103.4%
✗ Below median · Top 76.2% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
128.5%
✗ Below median · Top 64.8% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
3.6%
✓ Above median · Top 34.4% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
11.1%
✓ Above median · Top 10% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

54.2
How much did revenue grow in a year?
Revenue growth (YoY)
-19.5%
✗ Below median · Top 87.9% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-7.7%
✗ Below median · Top 81% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
209.3%
✓ Above median · Top 7.8% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
253.2%
✓ Above median · Top 6.7% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

86.4
Is the price expensive relative to earnings?
P/E (price-to-earnings)
6.1x
✓ Above median · Top 4.7% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.68x
✓ Above median · Top 22.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15